Synapse Open Synapse
Biology

StockWatch: Caribou Plunges as It Pursues Strategic Alternatives

GEN · · 9 min read

Caribou has halted trials of vispacabtagene regedleucel (vispa-cel, formerly CB-010) a treatment for relapsed or refractory B cell non-Hodgkin lymphoma; and of CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of patients with r/r multiple myeloma.

Latest from GEN